GlassScriptPhysician profile
Alyn L Benezette
NPI 1508863572
$15,595.55
in general payments reported to CMS, 2019-2025
68 companies · $2,312 in 2025
The $2,312 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,744 · 2020: $1,173 · 2021: $2,699 · 2022: $3,088 · 2023: $2,475 · 2024: $2,104 · 2025: $2,312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,842 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,841.61 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,352.14 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Pfizer INC. | $993.37 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $923.33 | 2019-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $873.11 | 2019-2024 | Xtampza |
| Supernus Pharmaceuticals, INC. | $736.84 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $690.34 | 2019-2025 | |
| Scilex Pharmaceuticals INC. | $526.48 | 2020-2024 | Ztlido |
| Ucb, INC. | $512.98 | 2020-2025 | Briviact, Nayzilam, Rystiggo |
| Genzyme Corporation | $437.47 | 2019-2023 | |
| Neurelis, INC. | $426.15 | 2020-2024 | Valtoco |
| Eisai INC. | $406.33 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $385.58 | 2019-2023 | Austedo Xr |
| Avanir Pharmaceuticals, INC. | $353.17 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $337.26 | 2022 | |
| Emd Serono, INC. | $289.69 | 2019-2025 | Mavenclad |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyn Benezette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.